Accelerate Diagnostics
AXDX
AXDX was delisted on the 14th of May, 2025.
103 hedge funds and large institutions have $533M invested in Accelerate Diagnostics in 2016 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 31 increasing their positions, 30 reducing their positions, and 11 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 3 → 6 (+3)
98% more capital invested
Capital invested by funds: $269M → $533M (+$264M)
73% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 11
8% more funds holding
Funds holding: 95 → 103 (+8)
3% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 30
58% less call options, than puts
Call options by funds: $2.35M | Put options by funds: $5.65M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NM
Newtyn Management
New York
|
+$13.3M |
| 2 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
+$10.9M |
| 3 |
NCGI
Next Century Growth Investors
Plymouth,
Minnesota
|
+$9.69M |
| 4 |
William Blair & Company
Chicago,
Illinois
|
+$5.79M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.92M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MGM
Miura Global Management
New York
|
-$6.64M |
| 2 |
William Blair Investment Management
Chicago,
Illinois
|
-$4.86M |
| 3 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$3.2M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$2.26M |
| 5 |
Barclays
London,
United Kingdom
|
-$1.91M |
AXDX Hedge Fund Activity: Q3 2016 in Review
103 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in Accelerate Diagnostics (AXDX) for Q3 2016, worth a combined $533M — up 98% from $269M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new AXDX positions and 11 closed out — a net gain of 8 holders — while 31 added to existing stakes and 30 trimmed.
The largest buyer was Newtyn Management, opening a new position worth an estimated $13.3M. The largest seller was Miura Global Management, cutting an estimated $6.64M.
- 103 institutional investors held Accelerate Diagnostics (AXDX) as of Q3 2016, up from 95 in Q2 2016.
- Funds reported $533M of Accelerate Diagnostics stock for Q3 2016, up 98% quarter-over-quarter.
- 19 funds opened new Accelerate Diagnostics positions in Q3 2016 and 11 closed out, a net change of +8 holders.
- The largest Accelerate Diagnostics buyer in Q3 2016 was Newtyn Management, an estimated $13.3M added.
- The largest Accelerate Diagnostics seller in Q3 2016 was Miura Global Management, an estimated $6.64M sold.
Based on aggregated 13F filings for Q3 2016.